Mylan and Upjohn, a division of Pfizer, to combine, creating a new champion for global health uniquely positioned to fulfill the world's need for medicine
- Details
- Category: Pfizer
HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company.
Amgen and Allergan's MVASI™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.).
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement
- Details
- Category: Bristol-Myers Squibb
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. ("Ono") announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.(1)
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
- Details
- Category: Novartis
Novartis today announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted Priority Review for its investigational sickle cell medicine crizanlizumab (SEG101). If FDA-approved, crizanlizumab is expected to represent the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease.
Boehringer Ingelheim acquires AMAL Therapeutics, significantly enriching its cancer immunology portfolio with novel cancer vaccines platform
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL's lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention
- Details
- Category: Novartis
Novartis, Amgen and Banner Alzheimer's Institute today announced the decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer's Prevention Initiative Generation Program. An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function.
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
- Details
- Category: Sanofi
The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). The target action date for the FDA decision is April 30, 2020. Isatuximab is an investigational monoclonal antibody that targets a specific epitope on the CD38 receptor of a plasma cell.
More Pharma News ...
- Pfizer completes acquisition of Therachon
- LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
- Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
- Sanofi and Google to develop new healthcare Innovation Lab
- Bristol-Myers Squibb provides update on pending merger with Celgene
- Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial
- Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease